Proxy Advisors Back Titan Medical
TORONTO, Ontario — Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is thrilled to announce a crucial recommendation from Glass Lewis. This independent proxy advisor has encouraged its clients to support the amalgamation with Conavi Medical. This recommendation arrives just in time for Titan's annual general and special meeting, where shareholders will deliberate on this important matter.
Why Glass Lewis’ Recommendation Matters
Glass Lewis has joined ISS as the second proxy advisory firm to endorse this amalgamation. Their recommendation reflects Titan's thoughtful approach to its restructuring and future trajectory. In their evaluation, they stress that shareholders would benefit from staying connected with an invigorated company that has exciting prospects for innovative technology and increased financial backing.
Strategic Restructuring and Focus
In its analysis, Glass Lewis acknowledged the operational and financial hurdles Titan has encountered. They recognized the company's considerable efforts toward restructuring, which includes cost reductions, licensing its intellectual property, and exploring various transactional options. This strategic shift follows Titan's decision in June 2023 to focus on becoming a leader in intellectual property licensing.
The Path to Amalgamation
Throughout this journey, Conavi Medical has emerged as a valuable partner, culminating in a collaborative agreement that demonstrates a strategic vision for Titan’s future. This important partnership could merge resources and expertise, leading to new prospects for both firms.
Importance of Shareholder Participation
Paul Cataford, Titan's Interim CEO and Board Chairman, underscored the need for shareholder involvement in this decision-making process. He urged shareholders to cast their votes, highlighting that every vote is crucial, especially as the deadline approaches. Cataford hopes for broad participation from shareholders to positively influence the outcome.
Why This Amalgamation is Significant
This proposed amalgamation promises not just to stabilize Titan's operations but also to drive growth through improved resources and a wider technological base. Partnering with Conavi Medical is set to deliver substantial advantages, including potential access to up to C$20 million in financial support, which could be pivotal for future developments.
Next Steps for Shareholders
Shareholders should be aware that the voting period is limited. It's essential to participate in this process. Votes need to be submitted by the specified deadline, prompting shareholders to act quickly.
Shareholder Q&A Session
To support dialogue among shareholders, Titan is organizing a Question and Answer session. This platform allows shareholders to express their concerns or seek clarification regarding the amalgamation and its potential implications.
About Titan Medical Inc.
Titan Medical (TSX: TMD; OTC: TMDIF) is dedicated to enhancing robotic-assisted surgical technology through innovation and a strong patent portfolio. The company is focused on exploring advanced opportunities to expand the frontiers of surgical practices.
About Conavi Medical Inc.
Conavi Medical is known for its imaging technologies, which are vital in minimally invasive procedures. Their flagship product, the Novasight Hybrid™ System, has received multiple approvals, demonstrating their commitment to improving cardiovascular treatments.
Frequently Asked Questions
What is the significance of the Glass Lewis recommendation?
Glass Lewis' recommendation reinforces the legitimacy of the amalgamation proposal, highlighting its strategic advantages for Titan’s shareholders.
How will the amalgamation affect Titan's future?
The amalgamation is anticipated to enhance Titan's financial stability and improve its capabilities in robotic-assisted surgery technology.
What actions should shareholders take?
Shareholders need to vote in favor of the amalgamation proposal before the specified deadline to ensure their opinions matter in this vital decision.
What is the deadline for voting?
Votes must be submitted by September 26, providing shareholders with limited time to make their voices heard.
How can shareholders get assistance with voting?
For any questions related to the voting process, shareholders can reach out to Shorecrest Group via telephone or email for support.
